Propel Rett Syndrome Treatment Forward—
With Our Support

Collaborate with IRSF—from early-stage research to clinical application—to reduce development timelines, optimize research, and meet the demand for Rett syndrome treatments more efficiently.

Expedite your Rett syndrome treatment development program.

IRSF can help your company through every phase of research and development, making the most of your investment.

Driving Progress Together

The International Rett Syndrome Foundation has hands-on experience helping partners through this process. We offer a wide range of assets, including:

21 Centers of Excellence Clinics

Clinical Trial Committee

Active & Engaged Rett Syndrome Community

Access to Regulatory Agencies

Preclinical Testing Platform

NIH-funded Natural History Database

Rett Syndrome Registry for Ongoing Data Collection

Funding for Early Stage Biotech & Human Clinical Trials

Ready to make a difference for Rett?
Let’s talk about how IRSF can help.

Why Rett?

Rett syndrome is in the unique position of having a known cause, dedicated research, and opportunity for effective treatments.

350,000 Individuals Living with Rett Worldwide

Base of Scientific Understanding

Clinical Network and Key Opinion Leaders

Existing FDA-Approved Treatment

One Causal Gene

Predictive Mouse Model

15 Years of Longitudinal Natural History Data

Established Centers of Excellence

Established Clinical Endpoints

The role of patient advocacy groups is critical to the drug development process. Our partnership and collaboration [with IRSF] were essential in educating the community about the various stages of clinical trials that are required for FDA approval. Additionally, the team at IRSF provided many useful insights and suggestions to assist in the recruiting of people living with Rett syndrome and their families into our studies.

Bill Keller

Bill Keller, Vice President, Patient Advocacy and Industry Relations, Acadia Pharmaceuticals

IRSF has facilitated critical connections between Taysha Gene Therapies and the Rett syndrome community to support our efforts to develop a gene therapy for the treatment of Rett syndrome. These connections allow us to provide transparent updates to families and identify opportunities for education, while also allowing families to share their perspectives, discoveries and experiences. These critical insights have helped inform our regulatory and clinical development approach.

Emily McGinnis

Emily McGinnis, Chief Patient & External Affairs Officer, Taysha Gene Therapies

We are delighted to continue our partnership with [IRSF] and its network of experts to accelerate the clinical development of ANAVEX 2-73 for the treatment of Rett syndrome.

Christopher U. Missling, PhD

Christopher U. Missling, PhD, President and Chief Executive, Anavex Life Sciences

Who We’ve Worked With

We partner with researchers in gene therapies and pharmaceutical treatment, from early stage to clinical trial.

Propel Rett Syndrome Treatment Forward— With Our Support